{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:37:34Z","timestamp":1794713854052,"version":"4.9.1"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40265-025-02169-x","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T03:03:47Z","timestamp":1742699027000},"page":"643-658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Current Drug Treatment for Acute and Recurrent Pericarditis"],"prefix":"10.1007","volume":"85","author":[{"given":"Aldo","family":"Bonaventura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Santagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vecchi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-785X","authenticated-orcid":false,"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"2169_CR1","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Y Adler","year":"2015","unstructured":"Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36:2921\u201364.","journal-title":"Eur Heart J"},{"key":"2169_CR2","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1001\/jama.2024.12935","volume":"332","author":"PC Cremer","year":"2024","unstructured":"Cremer PC, Klein AL, Imazio M. Diagnosis, risk stratification, and treatment of pericarditis: a review. JAMA. 2024;332:1090\u2013100.","journal-title":"JAMA"},{"key":"2169_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jacc.2019.11.021","volume":"75","author":"JG Chiabrando","year":"2020","unstructured":"Chiabrando JG, Bonaventura A, Vecchie A, Wohlford GF, Mauro AG, Jordan JH, et al. Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:76\u201392.","journal-title":"J Am Coll Cardiol"},{"key":"2169_CR4","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1016\/j.chest.2020.07.039","volume":"158","author":"A Vecchie","year":"2020","unstructured":"Vecchie A, Chiabrando JG, Dell MS, Bonaventura A, Mauro AG, Wohlford G, et al. Clinical presentation and outcomes of acute pericarditis in a large urban hospital in the United States of America. Chest. 2020;158:2556\u201367.","journal-title":"Chest"},{"key":"2169_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.amjcard.2021.08.048","volume":"160","author":"MG Del Buono","year":"2021","unstructured":"Del Buono MG, Vecchie A, Damonte JI, Chiabrando JG, Dell MS, Bonaventura A, et al. Pericarditis recurrence after initial uncomplicated clinical course. Am J Cardiol. 2021;160:112\u20136.","journal-title":"Am J Cardiol"},{"key":"2169_CR6","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1161\/CIRCULATIONAHA.105.542738","volume":"112","author":"M Imazio","year":"2005","unstructured":"Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112:2012\u20136.","journal-title":"Circulation"},{"key":"2169_CR7","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1056\/NEJMoa1208536","volume":"369","author":"M Imazio","year":"2013","unstructured":"Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369:1522\u20138.","journal-title":"N Engl J Med"},{"key":"2169_CR8","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1001\/archinte.165.17.1987","volume":"165","author":"M Imazio","year":"2005","unstructured":"Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, Moratti M, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165:1987\u201391.","journal-title":"Arch Intern Med"},{"key":"2169_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.7326\/0003-4819-155-7-201110040-00359","volume":"155","author":"M Imazio","year":"2011","unstructured":"Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155:409\u201314.","journal-title":"Ann Intern Med"},{"key":"2169_CR10","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/S0140-6736(13)62709-9","volume":"383","author":"M Imazio","year":"2014","unstructured":"Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383:2232\u20137.","journal-title":"Lancet"},{"key":"2169_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/FJC.0000000000001435","volume":"83","author":"GK Thomas","year":"2024","unstructured":"Thomas GK, Bonaventura A, Vecchie A, van Tassell B, Imazio M, Klein A, et al. Interleukin-1 blockers for the treatment of recurrent pericarditis: pathophysiology, patient-reported outcomes, and perspectives. J Cardiovasc Pharmacol. 2024;83:503\u201310.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2169_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023252","volume":"11","author":"A Brucato","year":"2022","unstructured":"Brucato A, Lim-Watson MZ, Klein A, Imazio M, Cella D, Cremer P, et al. Interleukin-1 trap rilonacept improved health-related quality of life and sleep in patients with recurrent pericarditis: results from the phase 3 clinical trial RHAPSODY. J Am Heart Assoc. 2022;11: e023252.","journal-title":"J Am Heart Assoc"},{"key":"2169_CR13","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.jacc.2023.03.406","volume":"81","author":"A Yesilyaprak","year":"2023","unstructured":"Yesilyaprak A, Kumar AK, Agrawal A, Verma B, Berglund F, Imazio M, et al. Prognostic value of etiology in patients with recurrent pericarditis. J Am Coll Cardiol. 2023;81:2056\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"2169_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jacasi.2024.06.008","volume":"4","author":"H Aikawa","year":"2024","unstructured":"Aikawa H, Fujino M, Nakao K, Nakai M, Kanaoka K, Sumita Y, et al. Diversity in acute autoimmune pericarditis: nationwide analysis of in-hospital outcomes and recurrence. JACC Asia. 2024;4:721\u201331.","journal-title":"JACC Asia."},{"key":"2169_CR15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jacasi.2024.08.006","volume":"4","author":"D Malandrino","year":"2024","unstructured":"Malandrino D, Weber B, Garshick MS, Abbate A. Diversity in acute pericarditis: picking the apples from the oranges. JACC Asia. 2024;4:732\u20134.","journal-title":"JACC Asia."},{"key":"2169_CR16","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1161\/CIRCULATIONAHA.107.761064","volume":"118","author":"M Imazio","year":"2008","unstructured":"Imazio M, Brucato A, Cumetti D, Brambilla G, Demichelis B, Ferro S, et al. Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. Circulation. 2008;118:667\u201371.","journal-title":"Circulation"},{"key":"2169_CR17","doi-asserted-by":"crossref","unstructured":"Giordani AS, Bocaj I, Vicenzetto C, Baritussio A, Gregori D, Scognamiglio F, et al. Aetiology, treatment and outcomes of pericarditis: long-term data from a longitudinal retrospective single-centre cohort. J Clin Med. 2024;13(22):6900.","DOI":"10.3390\/jcm13226900"},{"key":"2169_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jacbts.2020.11.016","volume":"6","author":"AG Mauro","year":"2021","unstructured":"Mauro AG, Bonaventura A, Vecchie A, Mezzaroma E, Carbone S, Narayan P, et al. The role of NLRP3 inflammasome in pericarditis: potential for therapeutic approaches. JACC Basic Transl Sci. 2021;6:137\u201350.","journal-title":"JACC Basic Transl Sci."},{"key":"2169_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.23736\/S0031-0808.21.04210-5","volume":"63","author":"A Vecchie","year":"2021","unstructured":"Vecchie A, Dell M, Mbualungu J, Ho AC, Benjamin VANT, Abbate A. Recurrent pericarditis: an update on diagnosis and management. Panminerva Med. 2021;63:261\u20139.","journal-title":"Panminerva Med"},{"key":"2169_CR20","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1002\/jcp.27436","volume":"234","author":"A Bonaventura","year":"2019","unstructured":"Bonaventura A, Montecucco F. Inflammation and pericarditis: are neutrophils actors behind the scenes? J Cell Physiol. 2019;234:5390\u20138.","journal-title":"J Cell Physiol"},{"key":"2169_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/FJC.0000000000001553","volume":"83","author":"A Vecchie","year":"2024","unstructured":"Vecchie A, Bonaventura A, Golino M, Thomas G, Abbate A. Novel therapeutic insights into the treatment of pericarditis: targeting the innate immune system. J Cardiovasc Pharmacol. 2024;83:377\u201383.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2169_CR22","first-page":"305","volume":"14","author":"E Lazarou","year":"2024","unstructured":"Lazarou E, Koutsianas C, Theofilis P, Lazaros G, Vassilopoulos D, Vlachopoulos C, et al. Interleukin-1 blockers: a paradigm shift in the treatment of recurrent pericarditis. Life (Basel). 2024;14:305.","journal-title":"Life (Basel)."},{"key":"2169_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.23736\/S2724-5683.23.06390-1","volume":"72","author":"A Bonaventura","year":"2024","unstructured":"Bonaventura A, Moroni F, Golino M, Del Buono MG, Vecchie A, Potere N, et al. IL-1 blockade in cardiovascular disease: an appraisal of the evidence across different inflammatory paradigms. Minerva Cardiol Angiol. 2024;72:477\u201388.","journal-title":"Minerva Cardiol Angiol."},{"key":"2169_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2459\/JCM.0000000000001684","volume":"26","author":"M Imazio","year":"2025","unstructured":"Imazio M, Collini V, Aimo A, Autore C, Bauce B, Biagini E, et al. Update on the diagnosis and treatment of pericardial diseases: a position paper of the Italian Society of Cardiology in collaboration with the study group on cardiomyopathies and pericardial diseases. J Cardiovasc Med (Hagerstown). 2025;26:29\u201337.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2169_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40256-024-00653-5","volume":"24","author":"Y Wan","year":"2024","unstructured":"Wan Y, He S, Wang S, Xu T, Qi M, Gan P. Efficacy and safety of interleukin-1 inhibitors in the management of patients with recurrent pericarditis: a systematic review and meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2024;24:537\u201345.","journal-title":"Am J Cardiovasc Drugs"},{"key":"2169_CR26","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1093\/eurheartj\/ehab452","volume":"43","author":"M Imazio","year":"2022","unstructured":"Imazio M, Lazaros G, Gattorno M, LeWinter M, Abbate A, Brucato A, et al. Anti-interleukin-1 agents for pericarditis: a primer for cardiologists. Eur Heart J. 2022;43:2946\u201357.","journal-title":"Eur Heart J"},{"key":"2169_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/ehjcvp\/pvx018","volume":"4","author":"LF Buckley","year":"2018","unstructured":"Buckley LF, Viscusi MM, Van Tassell BW, Abbate A. Interleukin-1 blockade for the treatment of pericarditis. Eur Heart J Cardiovasc Pharmacother. 2018;4:46\u201353.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"2169_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jacc.2023.04.046","volume":"82","author":"VY Myachikova","year":"2023","unstructured":"Myachikova VY, Maslyanskiy AL, Moiseeva OM, Vinogradova OV, Gleykina EV, Lavrovsky Y, et al. Treatment of idiopathic recurrent pericarditis with goflikicept: phase II\/III study results. J Am Coll Cardiol. 2023;82:30\u201340.","journal-title":"J Am Coll Cardiol"},{"key":"2169_CR29","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1016\/j.jacc.2017.02.072","volume":"69","author":"A Brucato","year":"2017","unstructured":"Brucato A, Valenti A, Maisch B. Acute and recurrent pericarditis: still idiopathic? J Am Coll Cardiol. 2017;69:2775.","journal-title":"J Am Coll Cardiol"},{"key":"2169_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10741-013-9382-y","volume":"18","author":"B Maisch","year":"2013","unstructured":"Maisch B, Rupp H, Ristic A, Pankuweit S. Pericardioscopy and epi- and pericardial biopsy\u2014a new window to the heart improving etiological diagnoses and permitting targeted intrapericardial therapy. Heart Fail Rev. 2013;18:317\u201328.","journal-title":"Heart Fail Rev"},{"key":"2169_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2459\/JCM.0b013e328351da6e","volume":"14","author":"A Buiatti","year":"2013","unstructured":"Buiatti A, Merlo M, Pinamonti B, De Biasio M, Bussani R, Sinagra G. Clinical presentation and long-term follow-up of perimyocarditis. J Cardiovasc Med (Hagerstown). 2013;14:235\u201341.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2169_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1161\/CIRCULATIONAHA.113.001531","volume":"128","author":"M Imazio","year":"2013","unstructured":"Imazio M, Brucato A, Barbieri A, Ferroni F, Maestroni S, Ligabue G, et al. Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study. Circulation. 2013;128:42\u20139.","journal-title":"Circulation"},{"key":"2169_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-000990","volume":"6","author":"J Berg","year":"2019","unstructured":"Berg J, Lovrinovic M, Baltensperger N, Kissel CK, Kottwitz J, Manka R, et al. Non-steroidal anti-inflammatory drug use in acute myopericarditis: 12-month clinical follow-up. Open Heart. 2019;6: e000990.","journal-title":"Open Heart."},{"key":"2169_CR34","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1002\/art.34644","volume":"64","author":"S Tarp","year":"2012","unstructured":"Tarp S, Bartels EM, Bliddal H, Furst DE, Boers M, Danneskiold-Samsoe B, et al. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2012;64:3511\u201321.","journal-title":"Arthritis Rheum"},{"key":"2169_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0748-7983(95)97157-2","volume":"21","author":"DC McMillan","year":"1995","unstructured":"McMillan DC, Leen E, Smith J, Sturgeon C, Preston T, Cooke TG, et al. Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol. 1995;21:531\u20134.","journal-title":"Eur J Surg Oncol"},{"key":"2169_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/10790268.2020.1773029","volume":"45","author":"A Park","year":"2022","unstructured":"Park A, Anderson D, Battaglino RA, Nguyen N, Morse LR. Ibuprofen use is associated with reduced C-reactive protein and interleukin-6 levels in chronic spinal cord injury. J Spinal Cord Med. 2022;45:117\u201325.","journal-title":"J Spinal Cord Med"},{"key":"2169_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.earlhumdev.2011.07.021","volume":"88","author":"G Demirel","year":"2012","unstructured":"Demirel G, Celik IH, Canpolat FE, Erdeve O, Oguz SS, Dilmen U. The effects of ibuprofen on sepsis parameters in preterm neonates. Early Hum Dev. 2012;88:195\u20136.","journal-title":"Early Hum Dev"},{"key":"2169_CR38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S0022-5223(19)35571-0","volume":"100","author":"PJ Horneffer","year":"1990","unstructured":"Horneffer PJ, Miller RH, Pearson TA, Rykiel MF, Reitz BA, Gardner TJ. The effective treatment of postpericardiotomy syndrome after cardiac operations. A randomized placebo-controlled trial. J Thorac Cardiovasc Surg. 1990;100:292\u20136.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2169_CR39","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jcmg.2024.04.010","volume":"17","author":"AL Klein","year":"2024","unstructured":"Klein AL, Wang TKM, Cremer PC, Abbate A, Adler Y, Asher C, et al. Pericardial diseases: international position statement on new concepts and advances in multimodality cardiac imaging. JACC Cardiovasc Imaging. 2024;17:937\u201388.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2169_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF00918351","volume":"8","author":"PJ Flynn","year":"1984","unstructured":"Flynn PJ, Becker WK, Vercellotti GM, Weisdorf DJ, Craddock PR, Hammerschmidt DE, et al. Ibuprofen inhibits granulocyte responses to inflammatory mediators. A proposed mechanism for reduction of experimental myocardial infarct size. Inflammation. 1984;8:33\u201344.","journal-title":"Inflammation"},{"key":"2169_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/0002-9149(80)90608-6","volume":"46","author":"BI Jugdutt","year":"1980","unstructured":"Jugdutt BI, Hutchins GM, Bulkley BH, Becker LC. Salvage of ischemic myocardium by ibuprofen during infarction in the conscious dog. Am J Cardiol. 1980;46:74\u201382.","journal-title":"Am J Cardiol"},{"key":"2169_CR42","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1161\/CIRCULATIONAHA.108.844753","volume":"121","author":"M Imazio","year":"2010","unstructured":"Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues in the management of pericardial diseases. Circulation. 2010;121:916\u201328.","journal-title":"Circulation"},{"key":"2169_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11776","volume":"7","author":"E Ceriani","year":"2025","unstructured":"Ceriani E, Agozzino F, Berra S, Gidaro A, Bindi P, Pavarani A, et al. Duration of disease and long-term outcomes in patients with difficult-to-treat recurrent pericarditis: a chronic condition treated with nonsteroidal anti-inflammatory drugs, colchicine, corticosteroids, and anti-interleukin-1 agents. ACR Open Rheumatol. 2025;7: e11776.","journal-title":"ACR Open Rheumatol."},{"key":"2169_CR44","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2021.12.247","volume":"162","author":"LE Targownik","year":"2022","unstructured":"Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022;162:1334\u201342.","journal-title":"Gastroenterology"},{"key":"2169_CR45","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(87)92641-9","volume":"2","author":"A Rodriguez de la Serna","year":"1987","unstructured":"Rodriguez de la Serna A, Guindo Soldevila J, Marti Claramunt V, Bayes de Luna A. Colchicine for recurrent pericarditis. Lancet. 1987;2:1517.","journal-title":"Lancet"},{"key":"2169_CR46","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1093\/eurheartj\/ehab221","volume":"42","author":"M Imazio","year":"2021","unstructured":"Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021;42:2745\u201360.","journal-title":"Eur Heart J"},{"key":"2169_CR47","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/heartjnl-2011-301306","volume":"98","author":"M Imazio","year":"2012","unstructured":"Imazio M, Brucato A, Forno D, Ferro S, Belli R, Trinchero R, et al. Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis. Heart. 2012;98:1078\u201382.","journal-title":"Heart"},{"key":"2169_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/ehjcvp\/pvv001","volume":"1","author":"SK Agarwal","year":"2015","unstructured":"Agarwal SK, Vallurupalli S, Uretsky BF, Hakeem A. Effectiveness of colchicine for the prevention of recurrent pericarditis and post-pericardiotomy syndrome: an updated meta-analysis of randomized clinical data. Eur Heart J Cardiovasc Pharmacother. 2015;1:117\u201325.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"2169_CR49","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12872-019-1190-4","volume":"19","author":"LL Lutschinger","year":"2019","unstructured":"Lutschinger LL, Rigopoulos AG, Schlattmann P, Matiakis M, Sedding D, Schulze PC, et al. Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome. BMC Cardiovasc Disord. 2019;19:207.","journal-title":"BMC Cardiovasc Disord"},{"key":"2169_CR50","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.tcm.2022.02.001","volume":"33","author":"M Melendo-Viu","year":"2023","unstructured":"Melendo-Viu M, Marchan-Lopez A, Guarch CJ, Roubin SR, Abu-Assi E, Meneses RT, et al. A systematic review and meta-analysis of randomized controlled trials evaluating pharmacologic therapies for acute and recurrent pericarditis. Trends Cardiovasc Med. 2023;33:319\u201326.","journal-title":"Trends Cardiovasc Med"},{"key":"2169_CR51","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1189\/jlb.1012510","volume":"94","author":"S Paschke","year":"2013","unstructured":"Paschke S, Weidner AF, Paust T, Marti O, Beil M, Ben-Chetrit E. Technical advance: Inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments. J Leukoc Biol. 2013;94:1091\u20136.","journal-title":"J Leukoc Biol"},{"key":"2169_CR52","first-page":"150","volume":"6","author":"U Lange","year":"2001","unstructured":"Lange U, Schumann C, Schmidt KL. Current aspects of colchicine therapy \u2013 classical indications and new therapeutic uses. Eur J Med Res. 2001;6:150\u201360.","journal-title":"Eur J Med Res"},{"key":"2169_CR53","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/med.20097","volume":"28","author":"B Bhattacharyya","year":"2008","unstructured":"Bhattacharyya B, Panda D, Gupta S, Banerjee M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev. 2008;28:155\u201383.","journal-title":"Med Res Rev"},{"key":"2169_CR54","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40261-014-0238-6","volume":"34","author":"S Wason","year":"2014","unstructured":"Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig. 2014;34:845\u201355.","journal-title":"Clin Drug Investig"},{"key":"2169_CR55","first-page":"1611","volume":"18","author":"DJ Wallace","year":"1991","unstructured":"Wallace DJ. Active idiopathic systemic lupus erythematosus in a 90-year-old woman requiring corticosteroid therapy. J Rheumatol. 1991;18:1611\u20132.","journal-title":"J Rheumatol"},{"key":"2169_CR56","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/phar.2674","volume":"42","author":"NC Schwier","year":"2022","unstructured":"Schwier NC, Cornelio CK, Boylan PM. A systematic review of the drug-drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies. Pharmacotherapy. 2022;42:320\u201333.","journal-title":"Pharmacotherapy"},{"key":"2169_CR57","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ahj.2022.06.002","volume":"252","author":"DL Dixon","year":"2022","unstructured":"Dixon DL, Patel J, Spence R, Talasaz AH, Abbate A, Wiggins BS. Select drug\u2013drug interactions with colchicine and cardiovascular medications: a review. Am Heart J. 2022;252:42\u201350.","journal-title":"Am Heart J"},{"key":"2169_CR58","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1093\/eurheartj\/ehq319","volume":"31","author":"M Imazio","year":"2010","unstructured":"Imazio M, Trinchero R, Brucato A, Rovere ME, Gandino A, Cemin R, et al. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010;31:2749\u201354.","journal-title":"Eur Heart J"},{"key":"2169_CR59","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/heartjnl-2023-323484","volume":"110","author":"V Collini","year":"2024","unstructured":"Collini V, De Martino M, Andreis A, De Biasio M, Gaspard F, Paneva E, et al. Efficacy and safety of colchicine for the treatment of myopericarditis. Heart. 2024;110:735\u20139.","journal-title":"Heart"},{"key":"2169_CR60","doi-asserted-by":"publisher","first-page":"e002599","DOI":"10.1136\/openhrt-2023-002599","volume":"11","author":"V Collini","year":"2024","unstructured":"Collini V, Andreis A, De Biasio M, De Martino M, Isola M, Croatto N, et al. Efficacy of colchicine in addition to anakinra in patients with recurrent pericarditis. Open Heart. 2024;11:e002599.","journal-title":"Open Heart."},{"key":"2169_CR61","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227\u2013337.","journal-title":"Eur Heart J"},{"key":"2169_CR62","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.hjc.2018.04.001","volume":"60","author":"G Lazaros","year":"2019","unstructured":"Lazaros G, Antonopoulos AS, Vlachopoulos C, Oikonomou E, Karavidas A, Chrysochoou C, et al. Predictors of switching from nonsteroidal anti-inflammatory drugs to corticosteroids in patients with acute pericarditis and impact on clinical outcome. Hellenic J Cardiol. 2019;60:357\u201363.","journal-title":"Hellenic J Cardiol"},{"key":"2169_CR63","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2459\/JCM.0000000000001618","volume":"25","author":"M Imazio","year":"2024","unstructured":"Imazio M. Medical therapy of pericarditis: tips and tricks for clinical practice. J Cardiovasc Med (Hagerstown). 2024;25:420\u20135.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2169_CR64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","volume":"21","author":"S Toldo","year":"2024","unstructured":"Toldo S, Abbate A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nat Rev Cardiol. 2024;21:219\u201337.","journal-title":"Nat Rev Cardiol"},{"key":"2169_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102763","volume":"20","author":"G Cavalli","year":"2021","unstructured":"Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, et al. Interleukin 1alpha: a comprehensive review on the role of IL-1alpha in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2021;20: 102763.","journal-title":"Autoimmun Rev"},{"key":"2169_CR66","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11886-021-01589-x","volume":"23","author":"A Vecchie","year":"2021","unstructured":"Vecchie A, Del Buono MG, Chiabrando GJ, Dentali F, Abbate A, Bonaventura A. Interleukin-1 and the NLRP3 inflammasome in pericardial disease. Curr Cardiol Rep. 2021;23:157.","journal-title":"Curr Cardiol Rep"},{"key":"2169_CR67","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2016.15826","volume":"316","author":"A Brucato","year":"2016","unstructured":"Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA. 2016;316:1906\u201312.","journal-title":"JAMA"},{"key":"2169_CR68","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/FJC.0000000000000847","volume":"76","author":"GF Wohlford","year":"2020","unstructured":"Wohlford GF, Buckley LF, Vecchie A, Kadariya D, Markley R, Trankle CR, et al. Acute effects of interleukin-1 blockade using anakinra in patients with acute pericarditis. J Cardiovasc Pharmacol. 2020;76:50\u20132.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2169_CR69","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJMoa2027892","volume":"384","author":"AL Klein","year":"2021","unstructured":"Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, et al. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med. 2021;384:31\u201341.","journal-title":"N Engl J Med"},{"key":"2169_CR70","first-page":"1494","volume":"57","author":"N Kougkas","year":"2018","unstructured":"Kougkas N, Fanouriakis A, Papalopoulos I, Bertsias G, Avgoustidis N, Repa A, et al. Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up. Rheumatology (Oxford). 2018;57:1494\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"2169_CR71","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1017\/S1047951119000672","volume":"29","author":"S Epcacan","year":"2019","unstructured":"Epcacan S, Sahin S, Kasapcopur O. Anaphylactic reaction to anakinra in a child with steroid-dependent idiopathic recurrent pericarditis and successful management with canakinumab. Cardiol Young. 2019;29:549\u201351.","journal-title":"Cardiol Young"},{"key":"2169_CR72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12969-020-00438-5","volume":"18","author":"S Signa","year":"2020","unstructured":"Signa S, D\u2019Alessandro M, Consolini R, Miniaci A, Bustaffa M, Longo C, et al. Failure of anti Interleukin-1 beta monoclonal antibody in the treatment of recurrent pericarditis in two children. Pediatr Rheumatol Online J. 2020;18:51.","journal-title":"Pediatr Rheumatol Online J"},{"key":"2169_CR73","doi-asserted-by":"publisher","first-page":"P155","DOI":"10.1186\/1546-0096-13-S1-P155","volume":"13","author":"K Theodoropoulou","year":"2015","unstructured":"Theodoropoulou K, von Scheven-G\u00eate A, Bressieux-Degueldre S, Prsa M, Angelini F, Boulos T, et al. A case of corticosteroid-dependent recurrent pericarditis with different response to two IL-1 blocking agents. Pediatr Rheumatol. 2015;13:P155.","journal-title":"Pediatr Rheumatol"},{"key":"2169_CR74","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/S0735-1097(21)03230-7","volume":"77","author":"S Chawla","year":"2021","unstructured":"Chawla S, Lak HM, Furqan M, Klein A. Use of canakinumab (illaris) for the management of autoimmune mediated recurrent pericarditis. J Am Coll Cardiol. 2021;77:1874.","journal-title":"J Am Coll Cardiol"},{"key":"2169_CR75","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejim.2023.03.034","volume":"113","author":"AM Pisacreta","year":"2023","unstructured":"Pisacreta AM, Mascolo R, Nivuori M, Dominioni CC, Gabiati C, Trotta L, et al. Acute pericarditis with pleuropulmonary involvement, fever and elevated C-reactive protein: a systemic autoinflammatory disease? A cohort study. Eur J Intern Med. 2023;113:45\u20138.","journal-title":"Eur J Intern Med"},{"key":"2169_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132945","volume":"423","author":"M Imazio","year":"2025","unstructured":"Imazio M, Brucato A, Lazaros G, Andreis A, Mascolo R, Berra S, et al. Outcomes of acute pericarditis with an inflammatory phenotype. Int J Cardiol. 2025;423: 132945.","journal-title":"Int J Cardiol"},{"key":"2169_CR77","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11882-010-0160-9","volume":"11","author":"JR Yu","year":"2011","unstructured":"Yu JR, Leslie KS. Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Curr Allergy Asthma Rep. 2011;11:12\u201320.","journal-title":"Curr Allergy Asthma Rep"},{"key":"2169_CR78","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1136\/annrheumdis-2014-205990","volume":"73","author":"G Lazaros","year":"2014","unstructured":"Lazaros G, Vasileiou P, Koutsianas C, Antonatou K, Stefanadis C, Pectasides D, et al. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. Ann Rheum Dis. 2014;73:2215\u20137.","journal-title":"Ann Rheum Dis"},{"key":"2169_CR79","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1177\/2047487319879534","volume":"27","author":"M Imazio","year":"2020","unstructured":"Imazio M, Andreis A, De Ferrari GM, Cremer PC, Mardigyan V, Maestroni S, et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: the IRAP (International Registry of Anakinra for Pericarditis) study. Eur J Prev Cardiol. 2020;27:956\u201364.","journal-title":"Eur J Prev Cardiol"},{"key":"2169_CR80","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14656566.2022.2054327","volume":"23","author":"A Vecchie","year":"2022","unstructured":"Vecchie A, Del Buono MG, Mauro AG, Cremer PC, Imazio M, Klein AL, et al. Advances in pharmacotherapy for acute and recurrent pericarditis. Expert Opin Pharmacother. 2022;23:681\u201391.","journal-title":"Expert Opin Pharmacother"},{"key":"2169_CR81","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.3390\/jcm13206051","volume":"13","author":"A Andreis","year":"2024","unstructured":"Andreis A, Dossi FC, De Ferrari GM, Alunni G, Imazio M. Anakinra-dependent recurrent pericarditis: the role of the R202Q variant of the MEFV gene. J Clin Med. 2024;13:6051.","journal-title":"J Clin Med"},{"key":"2169_CR82","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/art.24174","volume":"60","author":"P Picco","year":"2009","unstructured":"Picco P, Brisca G, Traverso F, Loy A, Gattorno M, Martini A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum. 2009;60:264\u20138.","journal-title":"Arthritis Rheum"},{"key":"2169_CR83","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijcard.2012.05.086","volume":"160","author":"D Vassilopoulos","year":"2012","unstructured":"Vassilopoulos D, Lazaros G, Tsioufis C, Vasileiou P, Stefanadis C, Pectasides D. Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). Int J Cardiol. 2012;160:66\u20138.","journal-title":"Int J Cardiol"},{"issue":"1425\u201331","key":"2169_CR84","volume":"164","author":"M Finetti","year":"2014","unstructured":"Finetti M, Insalaco A, Cantarini L, Meini A, Breda L, Alessio M, et al. Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. J Pediatr. 2014;164(1425\u201331): e1.","journal-title":"J Pediatr"},{"key":"2169_CR85","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.amjcard.2015.07.047","volume":"116","author":"S Jain","year":"2015","unstructured":"Jain S, Thongprayoon C, Espinosa RE, Hayes SN, Klarich KW, Cooper LT, et al. Effectiveness and safety of anakinra for management of refractory pericarditis. Am J Cardiol. 2015;116:1277\u20139.","journal-title":"Am J Cardiol"},{"key":"2169_CR86","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1177\/2048872619886309","volume":"9","author":"MH Shaukat","year":"2020","unstructured":"Shaukat MH, Singh S, Davis K, Torosoff M, Peredo-Wende R. Efficacy of anakinra for idiopathic and non-idiopathic pericarditis refractory or intolerant to conventional therapy. Eur Heart J Acute Cardiovasc Care. 2020;9:888\u201392.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2169_CR87","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1136\/heartjnl-2020-316898","volume":"106","author":"A Andreis","year":"2020","unstructured":"Andreis A, Imazio M, Giustetto C, Brucato A, Adler Y, De Ferrari GM. Anakinra for constrictive pericarditis associated with incessant or recurrent pericarditis. Heart. 2020;106:1561\u20135.","journal-title":"Heart"},{"key":"2169_CR88","doi-asserted-by":"publisher","first-page":"ytac357","DOI":"10.1093\/ehjcr\/ytac357","volume":"6","author":"C Conte","year":"2022","unstructured":"Conte C, Princi G, D\u2019Amario D, Sanna T, Pedicino D, Liuzzo G. Incessant pericarditis following the second dose of SARS-CoV-2 mRNA vaccine successfully treated with anakinra: a case report. Eur Heart J Case Rep. 2022;6:ytac357.","journal-title":"Eur Heart J Case Rep."},{"key":"2169_CR89","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.cjca.2022.10.027","volume":"39","author":"M Camilli","year":"2023","unstructured":"Camilli M, Viscovo M, Hohaus S, Lamendola P, Verrecchia E, Gerardino L, et al. Incessant pericarditis successfully treated with anakinra in a patient on active treatment for mediastinal lymphoma. Can J Cardiol. 2023;39:1154\u20137.","journal-title":"Can J Cardiol"},{"key":"2169_CR90","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2027892","volume":"384","author":"AL Klein","year":"2021","unstructured":"Klein AL, Imazio M, Paolini JF. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. Reply. N Engl J Med. 2021;384:1475\u20136.","journal-title":"N Engl J Med"},{"key":"2169_CR91","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032516","volume":"13","author":"M Imazio","year":"2024","unstructured":"Imazio M, Klein AL, Brucato A, Abbate A, Arad M, Cremer PC, et al. Sustained pericarditis recurrence risk reduction with long-term rilonacept. J Am Heart Assoc. 2024;13: e032516.","journal-title":"J Am Heart Assoc"},{"key":"2169_CR92","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cjco.2024.02.002","volume":"6","author":"A Brucato","year":"2024","unstructured":"Brucato A, Trotta L, Arad M, Cremer PC, Insalaco A, Klutstein M, et al. Absence of pericarditis recurrence in rilonacept-treated patients with COVID-19 and SARS-CoV-2 vaccination: results from the RHAPSODY long-term extension. CJC Open. 2024;6:805\u201310.","journal-title":"CJC Open."},{"key":"2169_CR93","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/heartjnl-2022-321328","volume":"109","author":"A Brucato","year":"2023","unstructured":"Brucato A, Wheeler A, Luis SA, Abbate A, Cremer PC, Zou L, et al. Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis. Heart. 2023;109:297\u2013304.","journal-title":"Heart"},{"key":"2169_CR94","doi-asserted-by":"publisher","first-page":"qyad003","DOI":"10.1093\/ehjimp\/qyad003","volume":"1","author":"PC Cremer","year":"2023","unstructured":"Cremer PC, Lin D, Luis SA, Petersen J, Abbate A, Jellis CL, et al. Pericardial late gadolinium enhancement and time to recurrence: a substudy from RHAPSODY, a phase 3 clinical trial of rilonacept in recurrent pericarditis. Eur Heart J Imaging Methods Pract. 2023;1:qyad003.","journal-title":"Eur Heart J Imaging Methods Pract."},{"key":"2169_CR95","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/ehjci\/jeae200","volume":"26","author":"PC Cremer","year":"2024","unstructured":"Cremer PC, Brucato A, Insalaco A, Lin D, Luis SA, Kwon DH, et al. Longitudinal cardiac magnetic resonance imaging following clinical response to rilonacept and prior to recurrence upon treatment suspension: a RHAPSODY subgroup analysis. Eur Heart J Cardiovasc Imaging. 2024;26:72\u20139.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2169_CR96","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.amjcard.2019.09.026","volume":"125","author":"M Imazio","year":"2020","unstructured":"Imazio M, Pivetta E, Palacio Restrepo S, Sormani P, Pedrotti P, Quarta G, et al. Usefulness of cardiac magnetic resonance for recurrent pericarditis. Am J Cardiol. 2020;125:146\u201351.","journal-title":"Am J Cardiol"},{"key":"2169_CR97","first-page":"47","volume":"14","author":"A Dmitrieva","year":"2018","unstructured":"Dmitrieva A, Shipaeva E, Schedrova M, Scott M, Lavrovsky Y, Samsonov M. Nonclinical characterization of the novel IL-1 heterodimeric fusion protein RPH-104. Immunome Res. 2018;14:47.","journal-title":"Immunome Res."},{"key":"2169_CR98","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1161\/CIRCULATIONAHA.124.069396","volume":"150","author":"A Abbate","year":"2024","unstructured":"Abbate A, Van Tassell B, Bogin V, Markley R, Pevzner DV, Cremer PC, et al. Results of international, double-blind, randomized, placebo-controlled, phase IIa study of interleukin-1 blockade with RPH-104 (Goflikicept) in patients with ST-segment-elevation myocardial infarction (STEMI). Circulation. 2024;150:580\u20132.","journal-title":"Circulation"},{"key":"2169_CR99","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/FJC.0000000000001635","volume":"84","author":"A Abbate","year":"2024","unstructured":"Abbate A, Van Tassell B, Bogin V, Markley R, Pevzner DV, Cremer PC, et al. Interleukin-1 blockade with RPH-104 (goflikicept) in patients with ST-segment elevation myocardial infarction: secondary end points from an international, double-blind, randomized, placebo-controlled, phase 2a study. J Cardiovasc Pharmacol. 2024;84:565\u201377.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2169_CR100","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ijcard.2011.01.027","volume":"147","author":"F Vianello","year":"2011","unstructured":"Vianello F, Cinetto F, Cavraro M, Battisti A, Castelli M, Imbergamo S, et al. Azathioprine in isolated recurrent pericarditis: a single centre experience. Int J Cardiol. 2011;147:477\u20138.","journal-title":"Int J Cardiol"},{"key":"2169_CR101","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.autrev.2019.04.001","volume":"18","author":"N Peiffer-Smadja","year":"2019","unstructured":"Peiffer-Smadja N, Domont F, Saadoun D, Cacoub P. Corticosteroids and immunosuppressive agents for idiopathic recurrent pericarditis. Autoimmun Rev. 2019;18:621\u20136.","journal-title":"Autoimmun Rev"},{"key":"2169_CR102","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.amjcard.2013.06.036","volume":"112","author":"M Moretti","year":"2013","unstructured":"Moretti M, Buiatti A, Merlo M, Massa L, Fabris E, Pinamonti B, et al. Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis. Am J Cardiol. 2013;112:1493\u20138.","journal-title":"Am J Cardiol"},{"key":"2169_CR103","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2459\/JCM.0000000000000260","volume":"17","author":"M Imazio","year":"2016","unstructured":"Imazio M, Lazaros G, Picardi E, Vasileiou P, Carraro M, Tousoulis D, et al. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. J Cardiovasc Med (Hagerstown). 2016;17:263\u20139.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2169_CR104","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.mayocp.2012.05.024","volume":"87","author":"MH Khandaker","year":"2012","unstructured":"Khandaker MH, Schaff HV, Greason KL, Anavekar NS, Espinosa RE, Hayes SN, et al. Pericardiectomy vs medical management in patients with relapsing pericarditis. Mayo Clin Proc. 2012;87:1062\u201370.","journal-title":"Mayo Clin Proc"},{"key":"2169_CR105","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jtcvs.2016.03.098","volume":"152","author":"EA Gillaspie","year":"2016","unstructured":"Gillaspie EA, Stulak JM, Daly RC, Greason KL, Joyce LD, Oh J, et al. A 20-year experience with isolated pericardiectomy: analysis of indications and outcomes. J Thorac Cardiovasc Surg. 2016;152:448\u201358.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2169_CR106","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00380-019-01464-4","volume":"35","author":"G Gatti","year":"2020","unstructured":"Gatti G, Fiore A, Ternacle J, Porcari A, Fiorica I, Poletti A, et al. Pericardiectomy for constrictive pericarditis: a risk factor analysis for early and late failure. Heart Vessels. 2020;35:92\u2013103.","journal-title":"Heart Vessels"},{"key":"2169_CR107","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.athoracsur.2015.02.054","volume":"100","author":"N Vistarini","year":"2015","unstructured":"Vistarini N, Chen C, Mazine A, Bouchard D, Hebert Y, Carrier M, et al. Pericardiectomy for constrictive pericarditis: 20 years of experience at the Montreal Heart Institute. Ann Thorac Surg. 2015;100:107\u201313.","journal-title":"Ann Thorac Surg"},{"key":"2169_CR108","doi-asserted-by":"publisher","first-page":"101","DOI":"10.14503\/THIJ-16-5772","volume":"44","author":"BC Depboylu","year":"2017","unstructured":"Depboylu BC, Mootoosamy P, Vistarini N, Testuz A, El-Hamamsy I, Cikirikcioglu M. Surgical treatment of constrictive pericarditis. Tex Heart Inst J. 2017;44:101\u20136.","journal-title":"Tex Heart Inst J"},{"key":"2169_CR109","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1053\/j.jvca.2021.02.020","volume":"35","author":"VC Liu","year":"2021","unstructured":"Liu VC, Fritz AV, Burtoft MA, Martin AK, Greason KL, Ramakrishna H. Pericardiectomy for constrictive pericarditis: analysis of outcomes. J Cardiothorac Vasc Anesth. 2021;35:3797\u2013805.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2169_CR110","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000527335","volume":"5","author":"MB Viana","year":"2022","unstructured":"Viana MB, de Aquino PEA, Estadella D, Ribeiro DA, Viana GSB. Cannabis sativa and Cannabidiol: a therapeutic strategy for the treatment of neurodegenerative diseases? Med Cannabis Cannabinoids. 2022;5:207\u201319.","journal-title":"Med Cannabis Cannabinoids."},{"key":"2169_CR111","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1074\/jbc.M109.069294","volume":"285","author":"E Kozela","year":"2010","unstructured":"Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z. Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta\/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem. 2010;285:1616\u201326.","journal-title":"J Biol Chem"},{"key":"2169_CR112","doi-asserted-by":"publisher","first-page":"21224","DOI":"10.1002\/jcp.28728","volume":"234","author":"Y Huang","year":"2019","unstructured":"Huang Y, Wan T, Pang N, Zhou Y, Jiang X, Li B, et al. Cannabidiol protects livers against nonalcoholic steatohepatitis induced by high-fat high cholesterol diet via regulating NF-kappaB and NLRP3 inflammasome pathway. J Cell Physiol. 2019;234:21224\u201334.","journal-title":"J Cell Physiol"},{"key":"2169_CR113","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3389\/fphys.2016.00559","volume":"7","author":"R Libro","year":"2016","unstructured":"Libro R, Scionti D, Diomede F, Marchisio M, Grassi G, Pollastro F, et al. Cannabidiol modulates the immunophenotype and inhibits the activation of the inflammasome in human gingival mesenchymal stem cells. Front Physiol. 2016;7:559.","journal-title":"Front Physiol"},{"key":"2169_CR114","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1021\/acs.jnatprod.0c00138","volume":"83","author":"C Liu","year":"2020","unstructured":"Liu C, Ma H, Slitt AL, Seeram NP. Inhibitory effect of cannabidiol on the activation of NLRP3 inflammasome is associated with its modulation of the P2X7 receptor in human monocytes. J Nat Prod. 2020;83:2025\u20139.","journal-title":"J Nat Prod"},{"key":"2169_CR115","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3390\/ijms20081833","volume":"20","author":"A Mabou Tagne","year":"2019","unstructured":"Mabou Tagne A, Marino F, Legnaro M, Luini A, Pacchetti B, Cosentino M. A novel standardized Cannabis sativa L. extract and its constituent cannabidiol inhibit human polymorphonuclear leukocyte functions. Int J Mol Sci. 2019;20:1833.","journal-title":"Int J Mol Sci"},{"key":"2169_CR116","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3390\/ph14030220","volume":"14","author":"CT Gomez","year":"2021","unstructured":"Gomez CT, Lairion F, Repetto M, Ettcheto M, Merelli A, Lazarowski A, et al. Cannabidiol (CBD) alters the functionality of neutrophils (PMN). Implications in the refractory epilepsy treatment. Pharmaceuticals (Basel). 2021;14:220.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2169_CR117","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.taap.2007.09.012","volume":"226","author":"HY Wu","year":"2008","unstructured":"Wu HY, Chu RM, Wang CC, Lee CY, Lin SH, Jan TR. Cannabidiol-induced apoptosis in primary lymphocytes is associated with oxidative stress-dependent activation of caspase-8. Toxicol Appl Pharmacol. 2008;226:260\u201370.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2169_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2018.02.016","volume":"329","author":"H Li","year":"2018","unstructured":"Li H, Kong W, Chambers CR, Yu D, Ganea D, Tuma RF, et al. The non-psychoactive phytocannabinoid cannabidiol (CBD) attenuates pro-inflammatory mediators, T cell infiltration, and thermal sensitivity following spinal cord injury in mice. Cell Immunol. 2018;329:1\u20139.","journal-title":"Cell Immunol"},{"key":"2169_CR119","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/13543784.2024.2351513","volume":"33","author":"NM Naya","year":"2024","unstructured":"Naya NM, Kelly J, Hogwood A, Abbate A, Toldo S. Therapeutic potential of cannabidiol (CBD) in the treatment of cardiovascular diseases. Expert Opin Investig Drugs. 2024;33:699\u2013712.","journal-title":"Expert Opin Investig Drugs"},{"key":"2169_CR120","first-page":"e169","volume":"131","author":"N Martinez-Naya","year":"2022","unstructured":"Martinez-Naya N, Nirar AH, Kim MM, Mauro AG, Mezzaroma E, Narayan P, Hamer A, Bolton J, Abbate A, Toldo S. Protective effects of cannabidiol in a mouse model of acute pericarditis. Circ Res. 2022;131:e169\u201390.","journal-title":"Circ Res"},{"key":"2169_CR121","unstructured":"Cardiol therapeutics announces positive topline data from its phase II MAvERIC-pilot study investigating CardiolRx (TM) for recurrent pericarditis. https:\/\/www.newsfilecorp.com\/release\/212811\/Cardiol-Therapeutics-Announces-Positive-Topline-Data-from-its-Phase-II-MAvERICPilot-Study-Investigating-CardiolRxTM-for-Recurrent-Pericarditis. Last Accessed 7 Aug 2024."},{"key":"2169_CR122","unstructured":"Cardiol Therapeutics to Advance CardiolRx\u2122 into a late-stage trial in patients with recurrent pericarditis. https:\/\/www.cardiolrx.com\/cardiol-therapeutics-to-advance-cardiolrx-into-a-late-stage-trial-in-patients-with-recurrent-pericarditis\/. Last Accessed 6 Dec 2024."},{"key":"2169_CR123","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/FJC.0000000000000053","volume":"63","author":"C Marchetti","year":"2014","unstructured":"Marchetti C, Chojnacki J, Toldo S, Mezzaroma E, Tranchida N, Rose SW, et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol. 2014;63:316\u201322.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2169_CR124","doi-asserted-by":"publisher","first-page":"77","DOI":"10.31083\/j.rcm2403077","volume":"24","author":"A Bonaventura","year":"2023","unstructured":"Bonaventura A, Thomas GK, Golino M, Mauro AG, Vecchie A, Del Buono MG, et al. Novel pathophysiological, diagnostic and therapeutic concepts in acute and recurrent pericarditis. Rev Cardiovasc Med. 2023;24:77.","journal-title":"Rev Cardiovasc Med"},{"key":"2169_CR125","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jamacardio.2023.4820","volume":"9","author":"RB Thorolfsdottir","year":"2024","unstructured":"Thorolfsdottir RB, Jonsdottir AB, Sveinbjornsson G, Aegisdottir HM, Oddsson A, Stefansson OA, et al. Variants at the interleukin 1 gene locus and pericarditis. JAMA Cardiol. 2024;9:165\u201372.","journal-title":"JAMA Cardiol."},{"key":"2169_CR126","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2459\/JCM.0000000000001669","volume":"25","author":"M Imazio","year":"2024","unstructured":"Imazio M, Faletra F, Zucco J, Mio C, Carraro M, Gava AM, et al. Genetic variants in patients with recurrent pericarditis. J Cardiovasc Med (Hagerstown). 2024;25:799\u2013804.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2169_CR127","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00059-002-2376-5","volume":"27","author":"Y Finkelstein","year":"2002","unstructured":"Finkelstein Y, Shemesh J, Mahlab K, Abramov D, Bar-El Y, Sagie A, et al. Colchicine for the prevention of postpericardiotomy syndrome. Herz. 2002;27:791\u20134.","journal-title":"Herz"},{"key":"2169_CR128","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.2014.11026","volume":"312","author":"M Imazio","year":"2014","unstructured":"Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312:1016\u201323.","journal-title":"JAMA"},{"key":"2169_CR129","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1136\/heartjnl-2015-307827","volume":"101","author":"P Meurin","year":"2015","unstructured":"Meurin P, Lelay-Kubas S, Pierre B, Pereira H, Pavy B, Iliou MC, et al. Colchicine for postoperative pericardial effusion: a multicentre, double-blind, randomised controlled trial. Heart. 2015;101:1711\u20136.","journal-title":"Heart"},{"key":"2169_CR130","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.recesp.2018.11.021","volume":"72","author":"A Sambola","year":"2019","unstructured":"Sambola A, Roca Luque I, Merce J, Alguersuari J, Francisco-Pascual J, Garcia-Dorado D, et al. Colchicine administered in the first episode of acute idiopathic pericarditis: a randomized multicenter open-label study. Rev Esp Cardiol (Engl Ed). 2019;72:709\u201316.","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"key":"2169_CR131","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/heartjnl-2020-317928","volume":"107","author":"AL Klein","year":"2020","unstructured":"Klein AL, Lin D, Cremer PC, Nasir S, Luis SA, Abbate A, et al. Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial. Heart. 2020;107:488\u201396.","journal-title":"Heart"},{"key":"2169_CR132","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14110","volume":"54","author":"MG Del Buono","year":"2024","unstructured":"Del Buono MG, Bonaventura A, Vecchie A, Moroni F, Golino M, Bressi E, et al. Pathogenic pathways and therapeutic targets of inflammation in heart diseases: a focus on Interleukin-1. Eur J Clin Invest. 2024;54: e14110.","journal-title":"Eur J Clin Invest"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02169-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02169-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02169-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T21:01:50Z","timestamp":1745614910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02169-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":132,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2169"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02169-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"23 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received no funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AA has served as a consultant for Kiniksa, Novo Nordisk, and Monte Rosa Therapeutics. All\u00a0the other authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AB and AA conceived the general structure of the manuscript. AB, DS, and AA drafted the first version of the manuscript. DS drafted Fig. . AA critically revised the manuscript. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}